Search research articles
Contact Us
Filters
Showing results (361-370 of 399) with videos related to
Page
of 40
Sort By:
Journal of the American Society of Nephrology : JASN
|
April 17, 2024
Set7 Methyltransferase and Phenotypic Switch in Diabetic Glomerular Endothelial Cells
Scott Maxwell, Jun Okabe, Harikrishnan Kaipananickal, et al.
Amino Acids
|
July 9, 2013
Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects
Josephine M Forbes, Karly C Sourris, Maximilian P J de Courten, et al.
The Journal of Clinical Investigation
|
December 12, 2018
Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis
Raelene J Pickering, Christos Tikellis, Carlos J Rosado, et al.
Nutrients
|
April 30, 2021
Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide
Sih Min Tan, Runa S J Lindblom, Mark Ziemann, et al.
Journal of Hypertension
|
March 14, 2007
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
Wouter B A Eijkelkamp, Zhongxin Zhang, Barry M Brenner, et al.
Circulation
|
December 28, 2018
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K McGuire, John H Alexander, Odd Erik Johansen, et al.
Diabetes
|
January 10, 2018
Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1)
Jiaze Li, Pacific Huynh, Aozhi Dai, et al.
Cardiovascular Diabetology
|
March 16, 2018
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Julio Rosenstock, Vlado Perkovic, John H Alexander, et al.
Diabetes Care
|
May 24, 2020
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Vlado Perkovic, Robert Toto, Mark E Cooper, et al.
Diabetes
|
February 18, 2026
Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease
Madhura Bose, Muthukumar Mohan, Jun Okabe, et al.
Page
of 40
Search research articles
Search
Showing results (361-370 of 399) with videos related to
Sort By:
Page
of 40
Journal of the American Society of Nephrology : JASN
|
April 17, 2024
Set7 Methyltransferase and Phenotypic Switch in Diabetic Glomerular Endothelial Cells
Scott Maxwell, Jun Okabe, Harikrishnan Kaipananickal, et al.
Amino Acids
|
July 9, 2013
Advanced glycation end products (AGEs) are cross-sectionally associated with insulin secretion in healthy subjects
Josephine M Forbes, Karly C Sourris, Maximilian P J de Courten, et al.
The Journal of Clinical Investigation
|
December 12, 2018
Transactivation of RAGE mediates angiotensin-induced inflammation and atherogenesis
Raelene J Pickering, Christos Tikellis, Carlos J Rosado, et al.
Nutrients
|
April 30, 2021
Targeting Methylglyoxal in Diabetic Kidney Disease Using the Mitochondria-Targeted Compound MitoGamide
Sih Min Tan, Runa S J Lindblom, Mark Ziemann, et al.
Journal of Hypertension
|
March 14, 2007
Renal function and risk for cardiovascular events in type 2 diabetic patients with hypertension: the RENAAL and LIFE studies
Wouter B A Eijkelkamp, Zhongxin Zhang, Barry M Brenner, et al.
Circulation
|
December 28, 2018
Linagliptin Effects on Heart Failure and Related Outcomes in Individuals With Type 2 Diabetes Mellitus at High Cardiovascular and Renal Risk in CARMELINA
Darren K McGuire, John H Alexander, Odd Erik Johansen, et al.
Diabetes
|
January 10, 2018
Diabetes Reduces Severity of Aortic Aneurysms Depending on the Presence of Cell Division Autoantigen 1 (CDA1)
Jiaze Li, Pacific Huynh, Aozhi Dai, et al.
Cardiovascular Diabetology
|
March 16, 2018
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA<sup>®</sup>): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk
Julio Rosenstock, Vlado Perkovic, John H Alexander, et al.
Diabetes Care
|
May 24, 2020
Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial
Vlado Perkovic, Robert Toto, Mark E Cooper, et al.
Diabetes
|
February 18, 2026
Epigenetic Regulation of VCAM-1 by Lipoxin A4 Is Renoprotective Against Diabetic Kidney Disease
Madhura Bose, Muthukumar Mohan, Jun Okabe, et al.
Page
of 40